Skip to main content

Artificial Intelligence

Filter by:

Antitrust Viewpoint Thumbnail

Read the latest edition of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, and regulatory activities related to AI, including about the Civil Investigative Demand the FTC recently served to ChatGPT developer OpenAI.

Read more
Viewpoint Thumbnail

Leaders of the Congressional Artificial Intelligence Caucus introduced a bill that would create a National Artificial Intelligence Research Resource (NAIRR) to provide AI-related resources to spur innovation and US competitiveness. Mintz Antitrust Practice Co-chair Bruce Sokler and ML Strategies’ Alex Hecht and Christian Fjeld discuss the bill and the three-year push for the NAIRR.

Read more
Viewpoint Thumbnail

Read the latest edition of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, and regulatory activities related to AI, including the White House’s voluntary framework for ensuring safe, secure, and trustworthy AI.

Read more
Viewpoint Thumbnail

Read the inaugural issue of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, or regulatory activities related to AI.

Read more
Health Care Viewpoints Thumbnail

The information age in which we live is reaching a new milestone with the development and ready access to conversational artificial intelligence based on advanced transformer algorithms, or AI chatbots, including their upcoming integration into multiple Internet search engines. This development creates exciting opportunities and potentially terrifying risks in the health care space. Inevitably, people will ask AI chatbot-enabled search engines for information on diseases, conditions, medicines, or medical devices and use the response in some way to make certain medical decisions. But what happens when the AI chatbot’s response is inaccurate or even provides advice that may lead to harm if the user follows it? Can AI chatbots be regulated by the U.S. Food and Drug Administration (FDA)? What are the liability implications if a user is harmed? We provide some initial thoughts on such legal issues in this post.

Read more
Sign up to receive email updates from Mintz.
Subscribe Now

Explore Other Viewpoints: